Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.

[1]  D. Gilliland,et al.  TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations , 2007, Leukemia.

[2]  A. Tefferi,et al.  Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. , 2007, Seminars in thrombosis and hemostasis.

[3]  D. Gilliland,et al.  Oncogenes in Myeloproliferative Disorders , 2007, Cell cycle.

[4]  M. Stratton,et al.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.

[5]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[6]  J. Dick,et al.  Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo , 2006, Proceedings of the National Academy of Sciences.

[7]  G. Massonnet,et al.  High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. , 2006, Blood.

[8]  H. Kantarjian,et al.  Lenalidomide therapy in myelofibrosis with myeloid metaplasia. , 2006, Blood.

[9]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[10]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[11]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[12]  R. Levine,et al.  Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.

[13]  I. Weissman,et al.  The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  H. Lodish,et al.  Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. , 2006, Blood.

[15]  I. Weissman,et al.  Stem cell research: paths to cancer therapies and regenerative medicine. , 2005, JAMA.

[16]  J. D. van der Walt,et al.  Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. , 2005, The New England journal of medicine.

[17]  Stefan N Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.

[18]  K. Kaushansky.  On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. , 2005, Hematology. American Society of Hematology. Education Program.

[19]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[20]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[21]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[22]  L. Zon,et al.  Loss of gata1 but not gata2 converts erythropoiesis to myelopoiesis in zebrafish embryos. , 2005, Developmental cell.

[23]  B. Paw,et al.  The pu.1 promoter drives myeloid gene expression in zebrafish. , 2004, Blood.

[24]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[25]  Markus G. Manz,et al.  Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice , 2004, Science.

[26]  W. Vainchenker,et al.  Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. , 2004, Experimental hematology.

[27]  M. Dullaers,et al.  Lentivirally transduced dendritic cells as a tool for cancer immunotherapy , 2003, The journal of gene medicine.

[28]  Irving L. Weissman,et al.  Prospective isolation of human clonogenic common myeloid progenitors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  L. Zon,et al.  FOG acts as a repressor of red blood cell development in Xenopus. , 2000, Development.

[30]  C. Eaves,et al.  Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. , 1999, Blood.

[31]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[32]  C. Dai,et al.  Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. , 1992, Blood.

[33]  S. Perrin,et al.  Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[35]  J. Cashman,et al.  Unregulated proliferation of primitive neoplastic progenitor cells in long-term polycythemia vera marrow cultures. , 1988, The Journal of clinical investigation.

[36]  G. Faguet,et al.  Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. , 1981, Blood.

[37]  T. Papayannopoulou,et al.  Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. , 1977, The American journal of medicine.

[38]  J. Adamson,et al.  Polycythemia vera: stem-cell and probable clonal origin of the disease. , 1976, The New England journal of medicine.

[39]  Prchal Jf,et al.  Letter: Bone-marrow responses in polycythemia vera. , 1974 .

[40]  A. Axelrad,et al.  Letter: Bone-marrow responses in polycythemia vera. , 1974, The New England journal of medicine.